About Provasculon
Provasculon is a Healthcare company based in Cambridge (United States) founded in 2007, and was acquired by Mesoblast in June 2013. New blood vessel growth is stimulated through SDF-1 regenerative solutions. Provasculon has raised $6 million across 1 funding round from investors including Biogen, Mesoblast and Partners HealthCare. The company was acqui-hired. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified. Its competitors include Portola Pharma, MyoKardia and Cellino; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2007 in Cambridge, United States, Provasculon is focused on regenerative medicine within the life sciences sector. Genetically engineered versions of the SDF-1 protein are developed to attract endothelial progenitor stem cells to damaged heart tissue, supporting new blood vessel formation post-heart attacks. Since 2013, operations have been maintained as a subsidiary of Mesoblast Limited.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website provasculon.com
- Social LinkedIn
- Acquired by Mesoblast (Jun 2013)
Funding Insights of Provasculon
Provasculon has successfully raised a total of $6M through 1 strategic funding round. The most recent funding activity was a Series A round of $6 million completed in March 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6M
- Total Rounds 1
- Last Round Series A — $6M
- First Round $6M
(Mar 2008)
- Investors Count 2
All 1 funding rounds of Provasculon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2008 | $6M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Provasculon
Provasculon has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Biogen, Mesoblast and Partners HealthCare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| partners.org | ||||
Therapies for neurodegenerative and immunology disorders are developed. | 1978 | biogen.com | Cambridge, United States | |
Biotherapeutics derived from proprietary adult stem cell-based technologies | 2004 | mesoblast.com | Melbourne, Australia |
Investor details for Provasculon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Provasculon
1 people are tracked at Provasculon (1 in team).
| Name | Role | Group |
|---|---|---|
Susan J Ward | Chairman | Team |
Complete people profiles for Provasculon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Provasculon
3 dated milestones of Provasculon across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Provasculon is founded.
- Funding First funding round of $6.0M.
- Exit Acquired by Mesoblast.
Competitors of Provasculon
Provasculon has 3 listed competitors in our database, 3 of them funded. They include Portola Pharma, MyoKardia and Cellino.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| portola.com | 2003 | San Francisco, United States | $296.09M | 369 | Therapeutics for cardiovascular and autoimmune diseases are developed. | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies |
Detailed competitors of Provasculon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Provasculon (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Provasculon
Provasculon was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Provasculon is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Provasculon is a funded company, having raised a total of $6M across 1 funding round to date. The company's 1st funding round was a Series A of $6M, raised on Mar 2008.
Founded in 2007 in Cambridge, United States, Provasculon is focused on regenerative medicine within the life sciences sector. Genetically engineered versions of the SDF-1 protein are developed to attract endothelial progenitor stem cells to damaged heart tissue, supporting new blood vessel formation post-heart attacks. Since 2013, operations have been maintained as a subsidiary of Mesoblast Limited.
Provasculon's top competitors include Cellino, MyoKardia and Portola Pharma.
Yes. Provasculon was acquired by Mesoblast in June 2013.